Valeo Pharma Inc. · OTC:VPHIF
Valeo Pharma — Investor Presentation (April 2024)
24 slides from Valeo Pharma's investor presentation, April 2024
Slide 1: Corporate Presentation April 2024
Bringing Healthcare Innovation to Canadians Corporate Presentation April 2024 TSX: VPH
Slide 2: Forward-Looking Statements
Forward-Looking Statements: This presentation, including the documents incorporated by reference herein, contains “forward-looking information” as defined under Canadian securities laws (collectively, “forward-looking statements”). All statements other than statements of historical fact contained in
Slide 3: Company Overview
Company Overview ➢ Fast-growing Canadian specialty pharma (Mtl H.O.) ➢ License/acquire Canadian rights to innovative commercial stage prescription drugs ➢ Pan Canadian commercial presence ➢ 100+ employees (~ 70 Sales Rep.) ➢ 99% CAGR Revenues (last 3 years) / Significant leverage built-in for contin
Slide 4: Focus Areas
Focus Areas ➢ 3 Therapeutics Areas: - Respiratory - Hospital Specialty - Ophthalmology ➢ 4 High Growth Assets: - Asthma: Enerzair / Atectura - Hospital: Redesca - Ophtha: Simbrinza ➢ Canada: - 10K MDs - 250 Hospitals - ~ 50K + visits / year TSX:VPH PAGE 4
Slide 5: Corporate Priorities
Corporate Priorities ➢ Continued Revenue Growth: - 2023 record revenues $54M, vs $27.7M in 2022, up 94% ➢ Accelerate path to profitability: - Q1-24 Adj. EBITDA loss $2.1M vs $4.5M in Q4-23, down 54% - Projected EBITDA positive in Q4-24 ➢ Secure additional products: - Leverage existing commercial inf
Slide 6: Transformative Product Additions
Transformative Product Additions Revenues ($M) 100 80 $77M $65M 60 $53.9M 40 $27.7M 20 $13.6M $7.5M 0 FY 20 A FY 21 A FY 22 A FY 23 A FY 24 E FY 25 F Hosp./Spec. Ophthalmology Respiratory VALUE PROPOSITION: Significant operating leverage available with nominal additional costs TSX:VPH PAGE 6
Slide 7: Portfolio: Significant Growth Potential
Portfolio: Significant Growth Potential ENERZAIR ATECTURA REDESCA OTHERS SIMBRINZA 0 10 20 30 40 50 60 70 80 90 2024 Estimated Sales ($M) Peak Sales Potential ($M) TSX:VPH PAGE 7
Slide 8: Respiratory / Allergy Business Unit
Bringing Healthcare Innovation to Canadians Respiratory / Allergy Business Unit TSX: VPH
Slide 9: Asthma: Canadian Market Dynamics
Asthma: Canadian Market Dynamics ➢ 3.8 million Canadian asthma sufferers ➢ 1 million Suffer from moderate to severe ➢ ~ 40% Suffer from poor symptoms control $1.08B* TRIPLE agents (Corticosteroids + DUAL agents (Corticosteroids + 2 Bronchodilators) ~$220M Bronchodilator) ~$330M Single Agent Dual Age
Slide 10: Asthma: Enerzair / Atectura
ASTHMA: ENERZAIR / ATECTURA Launched in Q4-21 Triple Agent Therapy triple combination First in Class ICS/LABA/LAMA 350K Targeted patients population $90M + Peak sales 42% reduction in exacerbations vs Advair Fully reimbursed (Private & Public) Launched in Q4-21 Dual Agent Therapy Dual combination LA
Slide 11: Enerzair / Atectura: Prescription Trends
Enerzair / Atectura: Prescription Trends (Feb. 2024) # of Prescribers # of Prescriptions 4,000 90,000 3,604 81,759 3,472 78,002 3,500 3,315 80,000 73,991 3,146 70,467 2,967 70,000 67,234 3,000 2,825 63,470 2,668 59,954 2,503 60,000 56,021 2,361 52,367 2,500 2,208 48,813 2,036 50,000 45,031 1,889 41,
Slide 12: Hospital Specialty Business Unit
Bringing Healthcare Innovation to Canadians Hospital Specialty Business Unit TSX: VPH
Slide 13: Low Molecular Weight Heparin (LMWH)
Low Molecular Weight Heparin (LMWH) LMWH: Anticoagulant medications Usage: Prevention of blood clots, treatment of pulmonary embolism Heparins: Dalteparin: No Biosimilars Tinzaparin: No Biosimilars Enoxaparin: Redesca (~ 50% CDN market share) - Inclunox - Noromby - Elonox Why Biosimilars: As efficac
Slide 14: Low Molecular Weight Heparin: Canadian Market in $M
Low Molecular Weight Heparin: Canadian Market in $M (Dec. 23) DEC-23 $ TINZAPARIN $38,982,177 23% ➢ LMWH: ~ $170M in Canada DALTEPARIN $79,125,953 ➢ Ontario & Quebec: 70% of CDN market together 47% ➢ Enoxaparin: $51M market in Canada, and only LMWH with approved biosimilars ➢ Enoxaparin: 30% of all
Slide 15: Redesca (Biosimilar): LMWH Biosimilar Market Insight
Redesca® (Biosimilar) LMWH Biosimilar Market insight: Feb.-24 Monthly - IQVIA Launched in Q1-21 Target market: $170M 100% $35M Peak sales 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Mar-23 Apr-23 May-23 Jun-23 Jul-23 Aug-23 Sep-23 Oct-23 Nov-23 Dec-23 Jan-24 Feb-24 REDESCA 55% 54% 57% 53% 55% 54% 50% 52%
Slide 16: Ophthalmology Business Unit
Bringing Healthcare Innovation to Canadians Ophthalmology Business Unit TSX: VPH
Slide 17: Ophthalmology: Glaucoma Product
Ophthalmology: Glaucoma Product Launched in Q4-22 Target market: - 400,000 Canadians, - 1,200 ophthalmologists $60M market size Current market share: 18% Market CAGR: 4-5% Full commercial reach TSX:VPH PAGE 17
Slide 18: Financials & Summary
Financials & Summary TSX: VPH
Slide 19: Last 8 Qtrs: Net Revenues / Business Units
Last 8 Qtrs: Net Revenues / Business Units 16,000 14,000 12,000 10,000 8,000 6,000 4,000 2,000 - Q2-22 Q3-22 Q4-22 Q1-23 Q2-23 Q3-23 Q4-23 Q1-24 Respiratory/Allergy Ophthalmology Specialty and Base • Continued growth in Respiratory/Allergy • Return to growth for Specialty and Base • Ophthalmology ne
Slide 20: Yearly Revenues / Adj. EBITDA (Loss)
Yearly Revenues / ADJ. EBITDA (LOSS) 100 80 60 40 20 0 2022A 2023A 2024 F. 2025 E. 2026 E. -20 -40 Revenues Adjusted EBITDA OPEX • Increase in revenue momentum aligning with historical trend • OPEX reductions to mostly materialize in Q2-24 and ramping-up for remainder of FY-24 TSX:VPH PAGE 20
Slide 21: Capital Structure
Capital Structure, (at April 15, 2024) CAPITALIZATION MILLIONS Shares Outstanding (Share Price - $0.15) 98.6 Options/RSUs (avg. price, $0.56) 6,7 Warrants (avg. strike price $0.89) 19,7 Convertible debentures ($25.0M) 21.7 Management & Fully-Diluted Shares Outstanding 146.9 M Insiders aligned with s
Slide 22: Leadership
Leadership Management Steve Saviuk Founder, CEO, since 2003 Board of Directors Richard J. MacKay Richard Lajoie Chairman Board Member Former Vice-Chairman of Former President Bausch Health Pascal Tougas Stiefel Laboratories Canada CFO Former President Ortho Sanofi, Telus, CGI Dermatologics US, Steve
Slide 23: Investment Summary
Investment Summary ➢ Industry leading topline growth 2023, and beyond ➢ Commercial focus (no R&D / clinical trials) ➢ 4 growth assets launched/acquired last 2 yrs. ➢ Product portfolio peak sales potential ~ $200M ➢ Significant operating leverage already built-in ➢ Active BD&L efforts for additional
Slide 24: Contact Us
Contact Us PHONE 514-694-0150 EMAIL [email protected] WEB www.valeopharma.com